About Vtesse
Vtesse is a Healthcare company based in Gaithersburg (United States) founded in 2014, and was acquired by Sucampo in April 2017. Drugs for lysosomal storage diseases like Niemann-Pick are developed. Vtesse has raised $42 million across 2 funding rounds from investors including Pfizer, ARE and Sucampo. The company has 8 employees. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Avrobio, Raptor Pharma and Modis Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Vtesse was founded in 2014 and is headquartered in Gaithersburg, United States. Focus is placed on the biotechnology sector, where clinical studies for VTS-270a proprietary formulation of 2-hydroxypropyl-beta-cyclodextrinare conducted to treat Niemann-Pick disease type C. Pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases are also pursued. Support is provided by the Orphan Drug Accelerator, Cydan Development.
- Headquarters Gaithersburg, United States
- Employees 8
- Stage Acquired
- SectorsHealthcare
- Website vtessepharma.com
- Social LinkedIn
- Acquired by Sucampo (Apr 2017)
Funding Insights of Vtesse
Vtesse has successfully raised a total of $42M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42M
- Total Rounds 2
- Last Round Series A — $17M
- First Round $25M
(Jan 2015)
- Investors Count 5
All 2 funding rounds of Vtesse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $17M | Series A | – | Alexandria, Bay City Capital | – |
| Jan 2015 | $25M | Series A | – | New Enterprise Associates |
6 investors in total: 6 institutional.
Investors in Vtesse
Vtesse has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, ARE and Sucampo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Life science companies are funded through venture capital investments. | lundbeckfonden.com | Copenhagen, Denmark | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Prostone-based drugs are developed for gastrointestinal, ophthalmic, and oncology disorders. | 1996 | sucampo.com | Rockville, United States |
Investor details for Vtesse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Vtesse
4 dated milestones of Vtesse across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Vtesse is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series A, of $17.0M.
- Exit Acquired by Sucampo.
Competitors of Vtesse
Vtesse has 3 listed competitors in our database, 2 of them funded. They include Avrobio, Raptor Pharma and Modis Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avrobio.com | 2016 | Cambridge, United States | $85.5M | 114 | Gene therapies for genetic diseases are developed using lentiviral technology. | |
| raptorpharma.com | 2005 | Novato, United States | 128 | Small molecule therapeutics for rare diseases are developed. | ||
| modistx.com | 2016 | Oakland, United States | $30M | Therapies for rare genetic mitochondrial diseases are developed. |
Detailed competitors of Vtesse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Vtesse (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vtesse
Complete news archive for Vtesse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vtesse
Vtesse was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Vtesse is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Vtesse is a funded company, having raised a total of $42M across 2 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Jan 2015.
Vtesse has 8 employees.
Vtesse was founded in 2014 and is headquartered in Gaithersburg, United States. Focus is placed on the biotechnology sector, where clinical studies for VTS-270a proprietary formulation of 2-hydroxypropyl-beta-cyclodextrinare conducted to treat Niemann-Pick disease type C. Pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases are also pursued. Support is provided by the Orphan Drug Accelerator, Cydan Development.
Vtesse's top competitors include Raptor Pharma, Modis Therapeutics and Avrobio.
Vtesse has 6 investors. Key investors include Pfizer, ARE, Sucampo, Bay City Capital, and Lundbeck Foundation.
Yes. Vtesse was acquired by Sucampo in April 2017.